Reyon Pharmaceutical Co Ltd Working Capital to Net Assets Ratio
Reyon Pharmaceutical Co Ltd working capital to net assets ratio. Reyon Pharmaceutical Co Ltd (102460) has a Working Capital to Net Assets ratio of -23.1% as of September 2025. Working capital of ₩-53.78 Billion (current assets of ₩81.98 Billion minus current liabilities of ₩135.76 Billion) is measured against net assets of ₩233.12 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Reyon Pharmaceutical Co Ltd (2008–2024)
Working capital to net assets ratio of Reyon Pharmaceutical Co Ltd from 2008 to 2024. This chart shows how Reyon Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2008 to 2024. As of September 2025, the ratio stands at -23.1%, reflecting working capital of ₩-53.78 Billion against net assets of ₩233.12 Billion KRW. Explore 102460 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Reyon Pharmaceutical Co Ltd Working Capital to Net Assets Ratio by Year (2008–2024)
Reyon Pharmaceutical Co Ltd working capital to net assets ratio by year from 2008 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Reyon Pharmaceutical Co Ltd from 2008 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Reyon Pharmaceutical Co Ltd total assets.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -18.4% | ₩-46.09 Billion | ₩249.94 Billion | ₩89.44 Billion | ₩135.54 Billion | ▼ -8.1 pp |
| 2023 | -10.4% | ₩-25.79 Billion | ₩248.62 Billion | ₩99.81 Billion | ₩125.60 Billion | ▼ -35.0 pp |
| 2022 | 24.6% | ₩61.05 Billion | ₩247.77 Billion | ₩109.01 Billion | ₩47.95 Billion | ▼ -23.2 pp |
| 2021 | 47.8% | ₩117.30 Billion | ₩245.24 Billion | ₩164.80 Billion | ₩47.50 Billion | ▲ +17.8 pp |
| 2020 | 30.0% | ₩69.02 Billion | ₩230.09 Billion | ₩117.77 Billion | ₩48.75 Billion | ▼ -13.8 pp |
| 2019 | 43.8% | ₩97.27 Billion | ₩222.29 Billion | ₩130.31 Billion | ₩33.03 Billion | ▼ -37.0 pp |
| 2018 | 80.7% | ₩181.92 Billion | ₩225.39 Billion | ₩224.42 Billion | ₩42.51 Billion | ▲ +14.1 pp |
| 2017 | 66.6% | ₩146.21 Billion | ₩219.66 Billion | ₩161.69 Billion | ₩15.48 Billion | ▲ +11.8 pp |
| 2016 | 54.8% | ₩98.08 Billion | ₩179.10 Billion | ₩116.77 Billion | ₩18.69 Billion | ▼ -10.2 pp |
| 2012 | 65.0% | ₩82.14 Billion | ₩126.36 Billion | ₩109.84 Billion | ₩27.70 Billion | ▼ -11.7 pp |
| 2011 | 76.7% | ₩80.94 Billion | ₩105.47 Billion | ₩108.41 Billion | ₩27.47 Billion | ▲ +6.0 pp |
| 2009 | 70.7% | ₩42.26 Billion | ₩59.76 Billion | ₩62.06 Billion | ₩19.80 Billion | ▲ +1.7 pp |
| 2008 | 69.0% | ₩29.41 Billion | ₩42.63 Billion | ₩49.34 Billion | ₩19.92 Billion | — |